SCHEMBL3438987

SCHEMBL3438987

COC(=O)C(C)OC(=O)C(C)Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.54
HTR2A P28223 1/20 0.54
HTR2C P28335 1/20 0.54
HTR2B P41595 1/20 0.54
SMN1; SMN2 Q16637 5/20 0.49
LMNA P02545 5/20 0.49
MAPT P10636 4/20 0.49
ALOX12 P18054 1/20 0.49
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
TRPM4 Q8TD43 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
TDP1 Q9NUW8 2/20 0.42
POLB P06746 2/20 0.42
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
KMT2A Q03164 3/20 0.42
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2117203 0.89 SMN1; SMN2 (0.50) TSHRHTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL6910695 0.86 TSHR (0.72) TSHRHTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL11255192 0.86 TSHR (0.72) TSHRHTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL2117939 0.83 SMN1; SMN2 (0.54) TSHRHTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL16299847 0.78 TSHR (0.53) TSHRHTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL3438960 0.78 SMN1; SMN2 (0.48) TSHRHTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL29996006 0.76 SMN1; SMN2 (0.65) TSHRHTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL29106733 0.76 SMN1; SMN2 (0.65) TSHRHTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL10445559 0.76 SMN1; SMN2 (0.65) TSHRHTR2AHTR2CHTR2BSMN1; SMN2
SCHEMBL11393637 0.74 TSHR (0.51) TSHRHTR2AHTR2CHTR2BSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399696-B2 Functionalized biodegradable triclosan monomers and oligomers for controlled release BEZWADA BIOMEDICAL, LLC (US) 2013-03-19 US disclosed
US-8399696-B2 Functionalized biodegradable triclosan monomers and oligomers for controlled release BEZWADA BIOMEDICAL, LLC (US) 2013-03-19 US disclosed
US-20120289614-A1 FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE BEZWADA BIOMEDICAL, LLC (US) 2012-11-15 US disclosed
US-20120289614-A1 FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE BEZWADA BIOMEDICAL, LLC (US) 2012-11-15 US disclosed
US-8232422-B2 Functionalized biodegradable triclosan monomers and oligomers for controlled release BEZWADA BIOMEDICAL, LLC (US) 2012-07-31 US disclosed
US-8232422-B2 Functionalized biodegradable triclosan monomers and oligomers for controlled release BEZWADA BIOMEDICAL, LLC (US) 2012-07-31 US disclosed
US-20120095114-A1 FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE BEZWADA BIOMEDICAL, LLC (US) 2012-04-19 US disclosed
US-20120095114-A1 FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE BEZWADA BIOMEDICAL, LLC (US) 2012-04-19 US disclosed
US-8053591-B2 Functionalized biodegradable triclosan monomers and oligomers for controlled release BEZWADA BIOMEDICAL, LLC (US) 2011-11-08 US disclosed
US-8053591-B2 Functionalized biodegradable triclosan monomers and oligomers for controlled release BEZWADA BIOMEDICAL, LLC (US) 2011-11-08 US disclosed
US-20090105352-A1 FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE BEZWADA BIOMEDICAL, LLC (US) 2009-04-23 US disclosed
US-20090105352-A1 FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE BEZWADA BIOMEDICAL, LLC (US) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105352-A1 FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE LTN1, PARN, TLR3 TSHR 2565/4885HTR2A 767/4885HTR2C 1493/4885
US-20120095114-A1 FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE LTN1, PARN, TLR3 TSHR 2565/4885HTR2A 767/4885HTR2C 1493/4885
US-20120289614-A1 FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE LTN1, PARN, TLR3 TSHR 2565/4885HTR2A 767/4885HTR2C 1493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.